Atlas Trials

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07483567 · RECRUITING

Trial details

NCT number
NCT07483567
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
CLDN18.2 PositivePrimary Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Start date
2026-04-17
Primary completion
2030-06-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.